b'Source: Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis. Int J Cancer. 2023 Mar 1;152(5):865-878. doi: 10.1002/ijc.34299. Epub 2022 Oct 5. PMID: 36151863; PMCID: PMC9812887.WefoundsCD27andsCD30tobeassociateddifferentconclusionsintheirstudyofchangesin with [chronic lymphocytic leukemia/small lympho- serumlevelsofthebiomarkersin142service-cytic lymphoma] and FL, respectively, independentmembers with FL and 211 with DLBCL, with each of other markers, although both associations werematched to two healthy controls. 2approximately50%weakerforcasesdiagnosedThey found that increasing levels of sCD30 and 7.5 years post phlebotomy than for cases diagnosedCXCL13 started from the earliest collection times, closer in time to the date of blood collection. Thesewhile IL10 rose markedly closer to diagnosis. These patterns may suggest a later-stage role in the devel- results suggest that sCD30, CXCL13, and IL10 may opment of CLL/SLL and FL for the biologic effectscontribute to the etiology of FL and DLBCL and are captured by these markers, the researchers said. Onpotentialbiomarkersforthesenon-Hodgkinlym-the other hand, they noted, the study could not rulephoma subtypes, Levin and her colleagues wrote. out that the markers indicated early-stage disease. Likethepreviousteam,however,theycouldnot Another study examined the longitudinal changesdeterminewhethertheincreasingtrajectoriesof inimmuneactivationofthesesamebiomarkersthese markers may indicate early disease-induced plus IL10 before a diagnosis of NHL in active-dutyeffects or reflect the chronic stimulation of B-cells military personnel. Led by Lynn Levin, PhD, MPH,that promotes the development of FL and DLBCL of Walter Reed, the researchers reached somewhatsubtypes.Continued on Page 49 u47'